Despite a general drop in activity, there were many large deals, with a notable number of strategic tie-ups during January.
Month: January 2012
Lessons learned from Startup Genome Project
By Blackbox, a company responsible for creating the Startup Genome Report.
Tips on how to play the corporate venturing game
How corporations might want to think about corporate venturing…
Is the mountain of corporate cash an illusion?
The first of two articles by the Chartered Financial Analysts on where the corporate cash pile is going.
Gaule’s Question Time: Intel Capital
In our series of interviews with leading innovation and venture developers, Andrew Gaule, founder of the Corporate Venturing Network,
talks to Abdul Guefor, managing director of Intel Capital Treasury for Europe, the Middle East and Africa.
A new breed of corporation
Corporate venturing’s clock cannot be turned back and corporations are refining their strategies for the next generation.
Case study: Facebook
Facebook advertises its returns to corporations,
Xagenic heads out of the lab and into the money
The molecular diagnostics startup has landed $10m in a series A round partially funded by Qiagen, a molecular diagnostics and testing technology company.
ConforMIS solidifies $89m investment
The orthopaedic specialist has raised $89m in a series E round supported by investment group Axel Johnson and Asia-based government-backed investment funds.
Biogen Idec bids farewell to New Ventures
The pharmaceutical corporation is closing its corporate venturing unit, and will instead invest in strategic partnerships with mid-sized companies.
Profitero wins IBM SmartCamp
Nine startups competed for the title of 2011 IBM Global Entrepreneur of the Year, at the three day IBM SmartCamp Global Finals in Silicon Valley, with Ireland-based Profitero emerging victorious on Thursday. Almost 1,000 companies applied to participate in IBM SmartCamp events throughout 2011, with the stated aim of developing solutions for problems faced in… Continue reading Profitero wins IBM SmartCamp
FXall hoping for special effect from IPO
FXall, the electronic trading platform formerly known as FX Alliance, which is backed by a range of financial services firms, will offer its shares at between $13.50 and $15.50 when it floats.
Verastem gets $55m in IPO treatment
The oncological drug developer backed by the firm of SR One’s founder outstrips expectations as it raises $55m from its initial public offering, seeing its price rise after the first day of trading.
Cozi organises a $3m round
The Gannett-backed family-oriented online organiser provider pulls in $3m as it continues to grow.